Multicenter comparison of Neisseria meningitidis serogroup C anti-capsular polysaccharide antibody levels measured by a standardized enzyme-linked immunosorbent assay
Authors:
- 1 June 1994
- journal article
- research article
- Published by American Society for Microbiology in Journal of Clinical Microbiology
- Vol. 32 (6) , 1475-82
Abstract
A standardized enzyme-linked immunosorbent assay (ELISA) was used by 11 laboratories to measure levels of total serum antibody to Neisseria meningitidis serogroup C capsular polysaccharide in 16 unpaired pre- and postvaccination serum samples. Twelve serum samples were from adults, and four were from children aged 2, 3, 5, and 9. The between-laboratory coefficient of variation for pre- and postvaccination sera ranged from 16 to 59% and 11 to 21%, respectively. The average percent difference (absolute value) from the between-laboratory means for all prevaccination sera measured by each laboratory was 24%, whereas the average percent difference was 13% for all postvaccination sera. A postvaccination quality control serum was diluted three times to give optical densities on the high, middle, and low portions of the standard reference curve. The three dilutions were assayed by the 11 laboratories a total of 241 times and yielded an overall coefficient of variation of 20%. Antibody-binding inhibition curves showed that the standardized ELISA was specific for N. meningitidis serogroup C capsular polysaccharide antibody. Fifty percent inhibition of seven serum samples was obtained after reaction with an average concentration of 0.9 micrograms of meningococcal serogroup C polysaccharide per ml; an average of 93% inhibition was obtained with 50 micrograms of polysaccharide per ml. The acceptance and use of this standardized ELISA will reduce between-laboratory assay variability and ensure a more accurate and reproducible assessment of immunogenicity for vaccines under development.Keywords
This publication has 23 references indexed in Scilit:
- Quantitation of human IgG subclass antibodies to Haemophilus influenzae type b capsular polysaccharideJournal of Immunological Methods, 1992
- Development and phase 1 clinical testing of a conjugate vaccine against meningococcus A and CVaccine, 1992
- Caveats and suggestions for the ELISAJournal of Immunological Methods, 1991
- Measurement of anti-Haemophilus influenzae type b capsular polysaccharide antibodies by ELISAJournal of Immunological Methods, 1988
- Immunochemical Variables Affecting Radioantigen-Binding Assays of Antibody to Haemophilus tnjtuenzae Type b Capsular Polysaccharide in Childrens' SeraThe Journal of Infectious Diseases, 1987
- Factors influencing immunogenicity and safety of two Haemophilus influenzae type b polysaccharide vaccines in children 18 and 24 months of ageThe Pediatric Infectious Disease Journal, 1987
- Meningococcal Disease: Still with UsClinical Infectious Diseases, 1983
- Clinical evaluation of group A and group C meningococcal polysaccharide vaccines in infants.Journal of Clinical Investigation, 1975
- HUMAN IMMUNITY TO THE MENINGOCOCCUSJournal of Experimental Medicine, 1969
- A Quantitative Immunochemical Measure of thePrimary Interaction Between I*BSA and AntibodyThe Journal of Infectious Diseases, 1958